|Application ||WB, IHC, FC, ICC, E|
|Description||EIF2A is a 65-kD protein that catalyzes the formation of puromycin-sensitive 80S preinitiation complexes|
|Immunogen||Purified recombinant fragment of human EIF2A (AA: 448-576) expressed in E. Coli.|
|Formulation||Purified antibody in PBS with 0.05% sodium azide.|
|Other Names||Eukaryotic translation initiation factor 2A, eIF-2A, 65 kDa eukaryotic translation initiation factor 2A, Eukaryotic translation initiation factor 2A, N-terminally processed, EIF2A|
WB~~1/500 - 1/2000
IF~~1/200 - 1/1000
FC~~1/200 - 1/400
IHC~~1/200 - 1/1000
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||EIF2A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Functions in the early steps of protein synthesis of a small number of specific mRNAs. Acts by directing the binding of methionyl-tRNAi to 40S ribosomal subunits. In contrast to the eIF- 2 complex, it binds methionyl-tRNAi to 40 S subunits in a codon- dependent manner, whereas the eIF-2 complex binds methionyl-tRNAi to 40 S subunits in a GTP-dependent manner. May act by impiging the expression of specific proteins.|
|Tissue Location||Widely expressed. Expressed at higher level in pancreas, heart, brain and placenta|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a telomere specific protein, TERF2, which is a component of the telomere nucleoprotein complex. This protein is present at telomeres in metaphase of the cell cycle, is a second negative regulator of telomere length and plays a key role in the protective activity of telomeres. While having similar telomere binding activity and domain organization, TERF2 differs from TERF1 in that its N terminus is basic rather than acidic. ; ; ;
1. Mol Biol (Mosk). 2010 Sep-Oct;44(5):859-66. 2. Cancer Res. 2009 Feb 15;69(4):1545-52.
If you have any additional inquiries please email technical services at email@example.com.